| Coordinator, Site |
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon |
|
|
| Completed | 4 | 30 | US | CREON, Pancrelipase | AbbVie | Cystic Fibrosis, Chronic Pancreatitis | 07/23 | 08/23 | | |
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections |
|
|
| Completed | 4 | 73 | Europe, RoW | BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine | AbbVie | Facial Corrections, Facial Lines | 10/23 | 10/23 | | |
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder |
|
|
| Completed | 4 | 19 | US | Oxybutynin, Gelnique | AbbVie | Overactive Detrusor, Neurogenic Bladder | 08/23 | 10/23 | | |
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines |
|
|
| Recruiting | 4 | 100 | Canada, US | BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA | AbbVie | Upper Facial Lines | 12/24 | 04/25 | | |
NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) |
|
|
| Recruiting | 4 | 336 | Canada, US, RoW | Risankizumab, Deucravacitinib | AbbVie | Moderate Plaque Psoriasis | 03/25 | 03/26 | | |
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis |
|
|
| Recruiting | 4 | 200 | US | Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab | AbbVie | Genital Psoriasis, Scalp Psoriasis | 09/24 | 10/25 | | |
| Active, not recruiting | 4 | 461 | Europe, Canada, Japan, RoW | Upadacitinib, RINVOQ, ABT-494 | AbbVie, AbbVie Inc. | Atopic Dermatitis | 07/24 | 08/24 | | |
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy |
|
|
| Active, not recruiting | 3 | 112 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine, CC-486 | AbbVie, Roche-Genentech | Acute Myeloid Leukemia (AML) | 09/22 | 04/25 | | |
NCT04994535: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 426 | Europe, Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | Allergan | Platysma Prominence | 06/23 | 06/23 | | |
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles |
|
|
| Active, not recruiting | 3 | 1321 | Canada, US | MR-100A-01, Transdermal contraceptive delivery system | Mylan Technologies Inc., Mylan Inc. | Contraception | 01/25 | 01/25 | | |
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA |
|
|
| Completed | 3 | 199 | Europe, US, RoW | Dalbavancin single dose, Dalbavancin two dose, Comparator | AbbVie | Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections | 12/23 | 12/23 | | |
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
|
|
| Active, not recruiting | 3 | 140 | RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Forehead Lines | 09/24 | 09/24 | | |
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma |
|
|
| Recruiting | 3 | 1080 | Europe, US, RoW | Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine | Genmab, AbbVie | Follicular Lymphoma (FL) | 05/37 | 05/37 | | |
| Active, not recruiting | 3 | 429 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo | AbbVie | Giant Cell Arteritis (GCA) | 02/24 | 03/25 | | |
|
|
|
|
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) |
|
|
| Active, not recruiting | 3 | 286 | Europe, Canada, US, RoW | Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret | AbbVie | Hepatitis C Virus (HCV) | 08/24 | 08/24 | | |
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 3 | 880 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Dupilumab | AbbVie, AbbVie Inc. | Atopic Dermatitis | 03/24 | 07/24 | | |
| Recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 10/25 | 02/26 | | |
|
|
|
|
NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine |
|
|
| Recruiting | 3 | 450 | US | Ubrogepant, UBRELVY, Placebo for Ubrogepant | AbbVie | Migraine | 09/27 | 09/27 | | |
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab |
|
|
| Recruiting | 3 | 300 | US | Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B | AbbVie | Atopic Dermatitis | 08/25 | 03/26 | | |
| Active, not recruiting | 3 | 775 | Europe, Canada, US, RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Episodic Migraine | 11/24 | 11/24 | | |
|
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis |
|
|
| Active, not recruiting | 3 | 295 | Europe, Canada, Japan, US, RoW | Navitoclax, ABT-263, Ruxolitinib, Best Available Therapy (BAT) | AbbVie | Myelofibrosis (MF) | 11/24 | 01/25 | | |
|
|
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis |
|
|
| Not yet recruiting | 3 | 80 | US | Mesalamine, Delzicol, Placebo | AbbVie | Ulcerative Colitis (UC) | 07/26 | 07/26 | | |
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) |
|
|
| Completed | 3 | 438 | Europe, Canada, US, RoW | Linaclotide 72 μg (FC Participants), Placebo (FC Participants), Linaclotide 145 μg (IBS-C Participants), Linaclotide 290 μg (IBS-C Participants) | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation, Irritable Bowel Syndrome With Constipation | 05/24 | 05/24 | | |
| Active, not recruiting | 3 | 132 | Europe, Canada, Japan, US | Risankizumab, SKYRIZI, ABBV-066, Ustekinumab | AbbVie | Psoriasis | 02/24 | 12/24 | | |
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD |
|
|
| Recruiting | 3 | 152 | US | Cariprazine, VRAYLAR, AGN-241780, Placebo | AbbVie | Autism Spectrum Disorder | 10/24 | 11/24 | | |
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation |
|
|
| Recruiting | 3 | 116 | Europe, US | Linaclotide, Placebo for Linaclotide | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation (FC), Chronic Idiopathic Constipation (CIC) | 08/25 | 11/25 | | |
NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
|
|
| Recruiting | 3 | 800 | US | Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive | AbbVie | Endometriosis | 12/24 | 06/30 | | |
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine |
|
|
| Recruiting | 3 | 75 | US | Atogepant, QULIPTA | AbbVie | Chronic Migraine | 12/24 | 04/25 | | |
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants |
|
|
| Active, not recruiting | 3 | 159 | US | VOLITE XC, JUVÉDERM® VOLITE™ XC | AbbVie | Neck Lines | 10/24 | 10/24 | | |
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants |
|
|
| Active, not recruiting | 3 | 171 | Europe, Canada | HArmonyCa Lidocaine Injectable Gel | Allergan | Mid Face Volume Deficit | 05/25 | 05/25 | | |
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata |
|
|
| Recruiting | 3 | 1500 | Europe, Canada, Japan, US, RoW | Upadacitinib, Rinvoq, ABT-494, Placebo | AbbVie | Alopecia Areata | 05/25 | 01/28 | | |
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 698 | Europe, Canada, Japan, US, RoW | Telisotuzumab Vedotin, ABBV-399, Docetaxel | AbbVie | Non Small Cell Lung Cancer | 06/25 | 03/28 | | |
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars |
|
|
| Recruiting | 3 | 156 | Europe, Canada | ELAPR002f Injectable Gel, Saline Control | AbbVie | Atrophic Acne Scars | 08/25 | 08/25 | | |
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder |
|
|
| Recruiting | 3 | 280 | US | Cariprazine Flexible Dose | AbbVie | Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD) | 09/25 | 09/25 | | |
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension |
|
|
| Active, not recruiting | 3 | 515 | Europe, US, RoW | Bimatoprost (SR) | AbbVie | Open-Angle Glaucoma, Ocular Hypertension | 08/25 | 08/25 | | |
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma |
|
|
| Recruiting | 3 | 65 | US, RoW | XEN45 (Glaucoma Gel Stent) | AbbVie | Open-Angle Glaucoma | 08/25 | 08/25 | | |
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis |
|
|
| Recruiting | 3 | 480 | Europe, Canada, Japan, US, RoW | Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo | AbbVie | Rheumatoid Arthritis | 09/25 | 08/26 | | |
Step-Up HS, NCT05889182: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy |
|
|
| Recruiting | 3 | 1328 | Europe, Canada, Japan, US, RoW | Upadacitinib, ABT-494, RINVOQ, Placebo | AbbVie | Hidradenitis Suppurativa | 11/25 | 08/27 | | |
CANOVA, NCT03539744 / 2017-003838-88: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. |
|
|
| Active, not recruiting | 3 | 265 | Europe, Canada, Japan, US, RoW | Pomalidomide, Pomalyst, Dexamethasone, Venetoclax, ABT-199, GDC-0199 | AbbVie, Roche-Genentech | Multiple Myeloma | 08/26 | 08/26 | | |
|
NCT06063967: A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. |
|
|
| Recruiting | 3 | 276 | Europe, Canada, Japan, US, RoW | Risankizumab SC, ABBV-066, SKYRIZI, Placebo for risankizumab | AbbVie | Crohn's Disease | 03/26 | 02/28 | | |
NCT05125302: Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) |
|
|
| Recruiting | 3 | 1059 | US | Ubrogepant, Ubrelvy, Placebo-Matching Ubrogepant | AbbVie | Migraine | 05/26 | 05/26 | | |
TEMPLE, NCT05748483: Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine |
|
|
| Recruiting | 3 | 520 | Europe, Canada, RoW | Atogepant, QULIPTA, Placebo for Atogepant, Topiramate, Placebo for Topiramate | AbbVie | Migraine | 06/26 | 06/26 | | |
NCT04064827: A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) |
|
|
| Recruiting | 3 | 16 | US | Paricalcitol | AbbVie | Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT) | 06/26 | 10/26 | | |
NCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab |
|
|
| Recruiting | 3 | 40 | Europe, US | Adalimumab, Risankizumab, ABBV-066, Skyrizi | AbbVie | Juvenile Psoriatic Arthritis | 09/26 | 10/28 | | |
SELECT-SLE, NCT05843643: Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus |
|
|
| Recruiting | 3 | 1000 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ, Placebo | AbbVie | Systemic Lupus Erythematosus | 10/26 | 10/27 | | |
VIALE-T, NCT04161885 / 2019-002621-30: A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 3 | 424 | Europe, Canada, Japan, US, RoW | Venetoclax, ABT-199, GDC-0199, VENCLEXTA, Azacitidine, Best Supportive Care (BSC) | AbbVie | Acute Myeloid Leukemia (AML), Cancer | 11/26 | 11/26 | | |
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) |
|
|
| Recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/27 | 12/29 | | |
NCT05609630: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. |
|
|
| Recruiting | 3 | 90 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ, ABT-494, Tocilizumab | AbbVie | Juvenile Idiopathic Arthritis | 02/27 | 06/29 | | |
NCT05711394: A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine |
|
|
| Recruiting | 3 | 450 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689, Placebo-Matching Atogepant | AbbVie | Episodic Migraine | 03/28 | 05/28 | | |
NCT05782907: Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis. |
|
|
| Recruiting | 3 | 110 | Europe, Japan, US, RoW | Upadacitinib, RINVOQ | AbbVie | Ulcerative Colitis | 08/28 | 10/33 | | |
NCT05995353: A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease |
|
|
| Recruiting | 3 | 110 | Europe, US, RoW | Risankizumab, ABBV-066, SKYRIZI | AbbVie | Crohn's Disease | 04/29 | 04/29 | | |
NCT05707949: Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine |
|
|
| Enrolling by invitation | 3 | 250 | Europe, Canada, Japan, US, RoW | Atogepant, QULIPTA, AGN-241689 | AbbVie | Episodic Migraine | 11/29 | 11/29 | | |
EPCORE FL-1, NCT05409066 / 2021-000169-34: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma |
|
|
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Epcoritamab, GEN3013, Rituximab, Lenalidomide | Genmab, AbbVie | Follicular Lymphoma (FL) | 11/29 | 06/30 | | |
LIVIGNO-4, NCT06236438: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2/3 | 840 | Japan, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin | AbbVie | Non-Small Cell Lung Cancer | 10/31 | 10/31 | | |
NCT06345339: A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants |
|
|
| Recruiting | 2/3 | 2800 | US | Armour Thyroid, AGN-282176, Levothyroxine, Synthetic T4 | AbbVie | Hypothyroidism | 06/28 | 06/28 | | |
LIVIGNO-2, NCT06109272: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2/3 | 660 | Europe, US, RoW | Livmoniplimab, ABBV-151, Budigalimab, ABBV-181, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab | AbbVie | Hepatocellular Carcinoma | 09/30 | 09/30 | | |
NCT04853368 / 2020-005805-25: Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis |
|
|
| Terminated | 2 | 48 | Europe, US, RoW | ABBV-576, Galicaftor, Placebo, Navocaftor, ABBV-119 | AbbVie | Cystic Fibrosis (CF) | 06/23 | 06/23 | | |
|
AIM-CD, NCT05068284: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease |
|
|
| Terminated | 2 | 176 | Europe, Canada, Japan, US, RoW | ABBV-154, Placebo | AbbVie | Crohn's Disease | 07/23 | 07/23 | | |
|
NCT03339128 / 2017-003770-14: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children |
|
|
| Recruiting | 2 | 95 | Europe, Canada, US | Eluxadoline, Viberzi, Placebo | AbbVie | Irritable Bowel Syndrome | 12/26 | 12/26 | | |
NCT06151535: A Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel for the Improvement of Skin Quality in Adult Participants |
|
|
| Recruiting | 2 | 30 | Europe | ELAPR002f Injectable Gel | AbbVie | Skin Quality Deficit | 01/25 | 01/25 | | |
| Completed | 2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 03/24 | 03/24 | | |
NCT06241846: A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC |
|
|
| Recruiting | 2 | 100 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 02/27 | 02/29 | | |
NCT06257875: A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 200 | Japan, US | Lutikizumab Matching Placebo, Adalimumab Matching Placebo, Lutikizumab, ABT-981, Adalimumab, Humira | AbbVie | Ulcerative Colitis | 04/27 | 04/27 | | |
NCT05760313: A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide |
|
|
| Recruiting | 2 | 30 | Europe, US, RoW | Linaclotide, Linzess, Placebo | AbbVie, Ironwood Pharmaceuticals, Inc. | Functional Constipation | 09/25 | 09/25 | | |
NCT05141006: Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) |
|
|
| Active, not recruiting | 2 | 83 | Canada, US | BOTOX, OnabotulinumtoxinA, Botulinum Toxin Type A, Placebo for BOTOX | Allergan | Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | 07/24 | 02/25 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 01/25 | 04/25 | | |
NCT05771428: Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease |
|
|
| Active, not recruiting | 2 | 240 | Europe, Japan, US, RoW | ABBV-552, Placebo for ABBV-552 | AbbVie | Alzheimer's Disease (AD) | 08/24 | 09/24 | | |
NCT05216250: Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor |
|
|
| Active, not recruiting | 2 | 174 | Canada, US | BOTOX, Botulinum Toxin Type A, Placebo for BOTOX | AbbVie | Upper Limb Essential Tremor (UL ET) | 11/24 | 06/25 | | |
EAISE, NCT04309474 / 2019-003753-29: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke |
|
|
| Active, not recruiting | 2 | 121 | Europe, Canada, Japan, US, RoW | Elezanumab, ABT-555, Placebo | AbbVie | Acute Ischemic Stroke | 04/24 | 12/24 | | |
NCT06032546: A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 |
|
|
| Recruiting | 2 | 140 | Europe, Canada, Japan, US, RoW | Budigalimab, ABBV-181, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382 | AbbVie | Human Immuno-deficiency Virus (HIV) Disease | 04/25 | 10/26 | | |
NCT05570006: Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis |
|
|
| Recruiting | 2 | 40 | Europe, US | ABBV-668 | AbbVie | Ulcerative Colitis | 05/26 | 05/26 | | |
ELASCI, NCT04295538 / 2019-003752-36: Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI) |
|
|
| Active, not recruiting | 2 | 60 | Europe, Canada, Japan, US, RoW | Elezanumab, ABT-555, Placebo | AbbVie | Spinal Cord Injury (SCI) | 05/25 | 02/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 08/25 | 08/25 | | |
| Active, not recruiting | 2 | 270 | Europe, Canada, Japan, US, RoW | Telisotuzumab vedotin, ABBV-399 | AbbVie | Non-small Cell Lung Cancer | 10/25 | 10/25 | | |
M24-311, NCT06107413: Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
|
|
| Recruiting | 2 | 206 | Japan, US, RoW | ABBV-400, Bevacizumab, Folinic Acid, Fluorouracil, Irinotecan | AbbVie | Unresectable Metastatic Colorectal Cancer | 10/26 | 10/26 | | |
NCT05513703: A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 2 | 9 | Europe, Japan, US, RoW | Telisotuzumab Vedotin, ABBV-399 | AbbVie | Non Small Cell Lung Cancer | 03/25 | 03/26 | | |
LIVIGNO-1, NCT05822752: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) |
|
|
| Recruiting | 2 | 120 | Europe, Japan, US, RoW | Budigalimab, ABBV-181, Livmoniplimab, ABBV-151, Lenvatinib, Sorafenib | AbbVie | Hepatocellular Carcinoma | 12/26 | 02/27 | | |
NCT02899052 / 2019-004340-30: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) |
|
|
| Active, not recruiting | 2 | 120 | Europe, US, RoW | Carfilzomib, Kyprolis, Venetoclax, Venclexta, ABT-199, Dexamethasone | AbbVie, Genentech, Inc; Onyx Therapeutics, Inc. | Multiple Myeloma | 06/27 | 06/27 | | |
|
EPCORE NHL-6, NCT05451810: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma |
|
|
| Recruiting | 2 | 184 | US | Epcoritamab, ABBV-GMAB-3013 | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma | 08/27 | 05/29 | | |
NCT05291234: A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease |
|
|
| Recruiting | 2 | 195 | US | ABBV-916, Placebo | AbbVie | Alzheimer's Disease (AD) | 03/31 | 03/31 | | |
NCT04403763: Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia |
|
|
| Terminated | 1/2 | 80 | US | AGN-241622, Vehicle | AbbVie | Presbyopia | 12/22 | 12/22 | | |
NCT04807972 / 2020-005767-31: Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis |
|
|
| Completed | 1/2 | 40 | Europe, US, RoW | ABBV-927, Budiglimab, ABBV-181, modified FOLFIRINOX, mFFX | AbbVie | Pancreatic Cancer | 03/24 | 03/24 | | |
NCT06158854: A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving ABBV-383 as an Intravenous (IV) Infusion |
|
|
| Recruiting | 1/2 | 76 | Japan, US, RoW | ABBV-383, TNB-383B | AbbVie | Immunoglobulin Light Chain (AL) Amyloidosis | 12/25 | 02/28 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/24 | 03/27 | | |
NCT04499248: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension |
|
|
| Recruiting | 1/2 | 96 | Japan, US | AGN-193408 SR, Lumigan, Active Comparator, Sham Administration, Lumigan Vehicle, Vehicle | AbbVie | Open-angle Glaucoma, Ocular Hypertension | 08/27 | 08/27 | | |
NCT05956509: Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity |
|
|
| Active, not recruiting | 1/2 | 297 | US | ABBV-950, Botulinum toxin type A, BOTOX, OnabotulinumtoxinA, Placebo for ABBV-950 | AbbVie | Upper Limb Spasticity | 11/26 | 11/26 | | |
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 640 | RoW | YL201 for Injection | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 10/26 | 10/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Inc., Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
NCT05895266: A Study to Assess Drug-Drug Interaction Between ABBV-903 and Midazolam in Adult Healthy Volunteers |
|
|
| Completed | 1 | 24 | US | ABBV-903, Midazolam | AbbVie | Healthy Volunteer | 11/23 | 11/23 | | |
NCT06148181: A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants |
|
|
| Active, not recruiting | 1 | 99 | US | ABBV-141, Placebo for ABBV-141 | AbbVie | Healthy Volunteers | 01/25 | 01/25 | | |
NCT06158958: A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 192 | Japan, US, RoW | ABBV-303, Budigalimab, ABBV-181 | AbbVie | Solid Tumors | 01/28 | 01/28 | | |
NCT04189614: An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 65 | Europe, Japan, US, RoW | Cofetuzumab Pelidotin, ABBV-647 | AbbVie, Pfizer | Cancer, Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/24 | | |
M14-237, NCT02099058: A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors |
|
|
| Active, not recruiting | 1 | 237 | Europe, Japan, US, RoW | Osimertinib, Nivolumab, Telisotuzumab vedotin, ABBV-399, Erlotinib | AbbVie | Advanced Solid Tumors Cancer | 11/24 | 11/24 | | |
NCT06384352: A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 155 | US | YL211 | MediLink Therapeutics (Suzhou) Co., Ltd., Hoffmann-La Roche | Advanced Solid Tumors | 04/27 | 04/29 | | |
NCT05892757: Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers |
|
|
| Completed | 1 | 24 | US | Atogepant, QULIPTA, Ubrogepant, UBRELVY | AbbVie | Healthy Volunteers | 02/24 | 02/24 | | |
NCT05434234: A Study of YL201 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 196 | US, RoW | YL201 | MediLink Therapeutics (Suzhou) Co., Ltd. | Advanced Solid Tumor | 07/24 | 07/25 | | |
NCT04454658: Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis |
|
|
| Active, not recruiting | 1 | 21 | Europe, Japan, US, RoW | ABBV-744, Navitoclax, ABT-263, Ruxolitinib | AbbVie | Myelofibrosis (MF) | 11/24 | 11/24 | | |
NCT03639194: A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer |
|
|
| Completed | 1 | 132 | Japan, US, RoW | ABBV-011, SC-011, Budigalimab, ABBV-181 | AbbVie | Small Cell Lung Cancer | 01/24 | 01/24 | | |
NCT04041050: A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm |
|
|
| Active, not recruiting | 1 | 85 | Europe, Japan, US, RoW | Navitoclax, ABT-263, Ruxolitinib, Celecoxib, Celebrex | AbbVie | Myeloproliferative Neoplasm | 01/25 | 01/25 | | |
